InsiderDB

Lobbying disclosures · Lobbying report

HIMS: second_quarter 2026 lobbying report

Issues related to telehealth. Issues related to access to compounded drugs and drug shortages. Issues related to Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances. Issues related to diagnostic services.

Follow HIMS
Became public
Jul 8, 2026, 2:10 PM EDT
Event / period date
Not stated
Collected
Nov 9, 2026, 4:02 PM EST

Why this is connected

Exact legal-name match: Hims & Hers Health, Inc. (https://www.sec.gov/Archives/edgar/data/1773751/).

Reported lobbying amounts

Income: $60,000.00

These are different reporting measures. They are not added together or treated as spending on one particular bill.

Source evidence

Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/3ae14c88-63aa-40cb-9d92-bb01dc0912a7/","filing_uuid":"3ae14c88-63aa-40cb-9d92-bb01dc0912a7","filing_type":"Q2","filing_type_display":"2nd Quarter - Report","filing_year":2026,"filing_period":"second_quarter","filing_period_display":"2nd Quarter (Apr 1 - June 30)","filing_document_url":"https://lda.gov/filings/public/filing/3ae14c88-63aa-40cb-9d92-bb01dc0912a7/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Teresa Schofield","dt_posted":"2026-07-08T14:10:41-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"607 - 14th Street NW","registrant_address_2":"Suite 750","registrant_different_address":false,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20005","registrant":{"id":320918,"url":"https://lda.gov/api/v1/registrants/320918/","house_registrant_id":39554,"name":"KOUNTOUPES DENHAM CARR & REID, LLC","description":"Federal lobbying and consulting services","address_1":"607 - 14th Street NW","address_2":"Suite 750","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20005","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"NANCY HARPER MARLOW","contact_telephone":"+1 202-803-4585","dt_updated":"2026-07-22T14:29:32.717701-04:00"},"client":{"id":63958,"url":"https://lda.gov/api/v1/clients/63958/","client_id":63958,"name":"HIMS & HERS HEALTH, INC.","general_description":"Telehealth company","client_government_entity":null,"client_self_select":false,"state":"CA","state_display":"California","country":"US","country_display":"United States of America","ppb_state":"CA","ppb_state_display":"California","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2025-01-01"},"lobbying_activities":[{"general_issue_code":"HCR","general_issue_code_display":"Health Issues","description":"Issues related to telehealth. Issues related to access to compounded drugs and drug shortages. Issues related to Drug Enforcement Administration Rule (DEA407) concerning Telemedicine Prescribing of Controlled Substances. Issues related to diagnostic services.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":45200,"prefix":null,"prefix_display":null,"first_name":"LORI","nickname":null,"middle_name":null,"last_name":"DENHAM","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":10646,"prefix":null,"prefix_display":null,"first_name":"JULIE","nickname":null,"middle_name":"HERSHEY","last_name":"CARR","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":144880,"prefix":null,"prefix_display":null,"first_name":"LESLIE","nickname":null,"middle_name":null,"last_name":"ZELENKO","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":141462,"prefix":"ms","prefix_display":"MS.","first_name":"MARY","nickname":null,"middle_name":"DEE","last_name":"BEAL","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}

Price change after we could observe it

+8.78% HIMS

Adjusted closing prices from Nov 10, 2026 to Nov 11, 2026. SPY changed 1.32% over the same dates. The start is the first available close after both publication and collection. This is a price comparison, not an executed trade, investor profit, or a backtested strategy.

Congressional trading in HIMS

These disclosures provide context. Their presence does not establish a link between a trader and the event.

Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.